Skip to main content

Advertisement

Log in

Long term follow-up of Asian patients with chronic myeloid leukemia (CML) receiving allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-identical sibling—evaluation of risks and benefits

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only known curative therapy for patients with chronic myeloid leukemia (CML), but is associated with significant morbidity and mortality. The recent introduction of imatinib mesylate (STI-571) and reduced intensity transplant regimens has made the choice of primary treatment for patients with CML increasingly difficult. We have evaluated the outcome of 53 patients who have received allogeneic HSCT from human leukocyte antigen (HLA)-identical sibling donors between October 1985 and March 2002, determined the variables affecting the outcome, and tried to define indications for this aggressive approach. Successful engraftment occurred in 49 (98%) of evaluable patients. Acute graft-versus-host disease (GVHD) of grade II to IV severity was observed in 63% of the evaluable patients whereas the incidence of chronic GVHD was 57.5%. The Kaplan-Meier estimate of survival at 10 years was 54% [95% confidence interval (CI): 38–70%] and 31% (95% CI: 6–56%) for patients with first chronic phase and more advanced diseases, respectively. Multivariate analysis showed that younger age, absence of grade III-IV GVHD, the use of busulphan and cyclophosphamide (BuCy) as preparative regimen, and transplantation performed after January 1992 were factors associated with improved survival. Patients who were 30 years of age or younger who had transplantation done within 1 year after diagnosis during their first chronic phase of disease had a particularly good prognosis, with a probability of surviving 10 years of 72% (95% CI: 52–92%). We conclude that allogeneic HSCT remains a feasible option for Asian patients with CML. The most favorable outcome is observed in younger patients with early phase of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Barrett J, Childs R (2000) Non-myeloablative stem cell transplants. Br J Haematol 111:6–17

    Article  CAS  PubMed  Google Scholar 

  2. Blazar BR, Orr HT, Arthur DC, Kersey JH, Fillipovich AH (1985) Restriction fragment length polymorphism as markers of engraftment in allogeneic marrow transplantation. Blood 66:1436–1444

    CAS  PubMed  Google Scholar 

  3. Bortin MM, Horowitz MM, Rimm AA (1992) Progress report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 10:113–122

    CAS  PubMed  Google Scholar 

  4. Cervantes F, Robertson JE, Rozman C, Baccarani M, Tura S, Gomez GA, Braun TJ, Clarkson BD, Pereira A (1994) Long-term survivors in chronic granulocytic leukaemia: a study by the International CGL Prognosis Study Group. Italian Cooperative CML Study Group. Br J Haematol 87:293–300

    CAS  PubMed  Google Scholar 

  5. Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J, Ueno N, Giralt S, Anderlini P (2000) Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 111:18–29

    Article  CAS  PubMed  Google Scholar 

  6. Clift RA, Anasetti C (1997) Allografting for chronic myeloid leukaemia. Baillieres Clin Haematol 10:319–336

    CAS  PubMed  Google Scholar 

  7. Clift RA, Buckner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E, Deeg HJ, Doney KC, Fisher LD, Hansen JA, McDonald GB, Sanders JE, Schoch G, Storb R, Sullivan KM, Witherspoon RP, Appelbaum FR (1994) Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 84:2036–2043

    CAS  PubMed  Google Scholar 

  8. Copelan EA, Penza SL, Theil KS, Elder PJ, Bechtel TP, Tighe MB, Ezzone SA, Scholl MD, Belt PS, Young DC, Avalos BR (2000) The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy. Bone Marrow Transplant 26:1037–1043

    Article  CAS  PubMed  Google Scholar 

  9. Copelan EA, Penza SL (1999) Preparative regimens for stem cell transplantation. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P (eds) Hematology. Basic principles and practice, 3rd edn. Churchill Livingstone, New York, pp 1628–1642

  10. Cox DR (1972) Regression models and life tables. J R Stat Med 34:187–220

    Google Scholar 

  11. Devergie A, Blaise D, Attal M, Tigaud JD, Jouet JP, Vernant JP, Bordigoni P, Ifrah N, Dauriac C, Cahn JY, et al. (1995) Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood. 85:2263–2268

    Google Scholar 

  12. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 344:1031–1037

    Google Scholar 

  13. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 1038–1042

  14. Enright H, Daniels K, Arthur DC, Dusenbery KE, Kersey JH, Kim T, Miller WJ, Ramsay NK, Vercellotti GM, Weisdorf DJ, McGlave PB (1996) Related donor marrow transplant for chronic myeloid leukemia: patient characteristics predictive of outcome. Bone Marrow Transplant 17:537–542

    CAS  PubMed  Google Scholar 

  15. Goldman JM, Druker BJ (2001) Chronic myeloid leukemia: current treatment options. Blood. 98:2039–2042

    Google Scholar 

  16. Goldman JM, Szydlo R, Horowitz MM, Gale RP, Ash RC, Atkinson K, Dicke KA, Gluckman E, Herzig RH, Marmont A, et al. (1993) Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 82:2235–2238

    CAS  PubMed  Google Scholar 

  17. Gratwohl A, Herman J, Goldman JM, Arcese W, Devergie A, Frassoni F, Gahrton G, Kolb HJ, Niederwieser D, Ruutu T, Vernant JP, de Witte T, Apperley J (1998) Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 352:1087–1092

    Article  CAS  PubMed  Google Scholar 

  18. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA, Petersdorf EW, Radich J, Sanders JE, Storb RF, Sullivan KM, Anasetti C (1998) Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338:962–968

    Article  CAS  PubMed  Google Scholar 

  19. Horowitz MM, Rowlings PA, Passweg JR (1996) Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 17 [Suppl 3]:S5–S6

    Google Scholar 

  20. Kantarjian HM, Cortes J, O’Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D, Talpaz M (2002) Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 99:3547–3553

    Article  CAS  PubMed  Google Scholar 

  21. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O’Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645–652

    CAS  PubMed  Google Scholar 

  22. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481

    Google Scholar 

  23. Koh LP, Hwang WYK, Chuah CTH, Linn YC, Goh YT, Ng HJ, PHC Tan (2003) Imatinib mesylate (STI-571) given concurrently with non-myeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis. Bone Marrow Transplant. 31:305–308

    Google Scholar 

  24. Lee CK, Lie AK, Liang R, Au WY, Chen FE, Chim CS, Kwong YL (1999) Outcome of Chinese patients with chronic myeloid leukaemia (CML) underwent allogeneic bone-marrow transplantation (BMT). Am J Hematol 61:85–89

    Article  CAS  PubMed  Google Scholar 

  25. Mantel N. (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163–170

    CAS  PubMed  Google Scholar 

  26. Nowell P, Hungerford D (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132:1497

    Google Scholar 

  27. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994–1004

    Article  CAS  PubMed  Google Scholar 

  28. Ong YW, Tan P, Lim SH, Ng HW, Goh YT (1990) Bone marrow transplantation for treatment chronic myelogenous leukemia (CML)—preliminary experience in Singapore. Ann Acad Med Singapore 19:169–174

    CAS  PubMed  Google Scholar 

  29. Or R, Shapira MY, Resnick I, Amar A, Ackerstein A, Samuel S, Aker M, Naparstek E, Nagler A, Slavin S (2003) Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 101:441–445

    Article  CAS  PubMed  Google Scholar 

  30. Passweg J, Walker I, Sobocinski K, Rio B, Litzow M, Giralt S, Carreras E, Szydlo R, Bolwell B, Ilhan O, Seiter K, Maharaj D, Pasquini R, Carabasi M, Kolb H, Gale R, Schouter H, Cornelissen J, Goldman J, Gratwohl A, Klein J, Horowitz M (2001) Validation of EBMT risk score for recipients of allogeneic hematopoietic stem cell transplants for chronic myelogenous leukemia (CML) (abstract). Blood 98:349a

    Google Scholar 

  31. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) Consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825–828

    CAS  PubMed  Google Scholar 

  32. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O’Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99:3530–3539

    Article  CAS  PubMed  Google Scholar 

  33. Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340:1330–1340

    CAS  PubMed  Google Scholar 

  34. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, et al. (1986) Methotrexate and cyclosporine compared with cyclosporin alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 31:729–735

    Google Scholar 

  35. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, Erickson K, Flowers M, Hansen J, Loughran T, et al. (1991) Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 28:250–259

    CAS  PubMed  Google Scholar 

  36. Sullivan KM (1999) Graft-versus-host disease. In: Thomas ED, Blume KG, Forman SJ (eds) Hematopoietic cell transplantation, 2nd edn. Blackwell Science, Boston, pp 515–536

  37. Thomas ED, Clift RA, Fefer A, Appelbaum FR, Beatty P, Bensinger WI, Buckner CD, Cheever MA, Deeg HJ, Doney K, et al. (1986) Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 104:155–163

    Google Scholar 

  38. Wadhwa J, Szydlo RM, Apperley JF, Chase A, Bua M, Marin D, Olavarria E, Kanfer E, Goldman JM (2002) Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood 99:2304–2309

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors acknowledge the continued efforts of all nurses and junior medical staff in the bone marrow transplantation unit for the excellent care rendered to our patients. We also appreciate the support given by the colleagues from the diagnostic laboratories and stem cell processing laboratories.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to L. P. Koh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koh, L.P., Hwang, W.Y.K., Tan, C.H. et al. Long term follow-up of Asian patients with chronic myeloid leukemia (CML) receiving allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-identical sibling—evaluation of risks and benefits. Ann Hematol 83, 286–294 (2004). https://doi.org/10.1007/s00277-003-0810-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-003-0810-2

Keywords

Navigation